Sugi Predict

Sugi Predict / Compounds / SCHEMBL707356

SCHEMBL707356

SCHEMBL707356

CC(=O)Nc1cc(F)cc(Br)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.48
▸ IDO1 P14902 3/20 0.45
▸ MEN1 O00255 4/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ MAPT P10636 2/20 0.44
▸ POLB P06746 1/20 0.44
▸ RAB9A P51151 1/20 0.42
▸ GAA P10253 2/20 0.42
▸ TDP1 Q9NUW8 2/20 0.42
▸ MAP4K4 O95819 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ NAPRT Q6XQN6 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ ACP1 P24666 1/20 0.40
▸ CA12 O43570 1/20 0.39
▸ BRD4 O60885 1/20 0.39
▸ NR1I2 O75469 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13414535 0.86 LMNA (0.58) LMNAIDO1MEN1KMT2AALDH1A1
SCHEMBL7978815 0.86 LMNA (0.58) LMNAIDO1MEN1KMT2AALDH1A1
SCHEMBL22864579 0.86 LMNA (0.58) LMNAIDO1MEN1KMT2AALDH1A1
SCHEMBL29556931 0.82 MAPK14 (0.43) LMNAMEN1KMT2AALDH1A1MAPT
SCHEMBL25262103 0.82 ACP1 (0.41) LMNAMEN1KMT2AALDH1A1MAPT
SCHEMBL26328327 0.81 SMN1; SMN2 (0.43) MEN1KMT2AMAPTRAB9AGAA
SCHEMBL29418058 0.81 SMN1; SMN2 (0.43) MEN1KMT2AMAPTRAB9AGAA
SCHEMBL20560189 0.81 ACP1 (0.40) LMNAMEN1KMT2AALDH1A1MAPT
SCHEMBL14992464 0.78 KMT2A (0.59) LMNAIDO1MEN1KMT2AALDH1A1
SCHEMBL5690802 0.78 MEN1 (0.59) LMNAMEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435066-B2 Substituted tricyclic compounds LUPIN LIMITED (IN) 2025-10-07 — — US disclosed
CN-119630672-A Camptothecin derivative and conjugate thereof, and preparation method and medical application thereof 一线医药（杭州）有限公司 2025-03-14 — — CN disclosed
CN-119219653-A Camptothecin derivatives 海南先声再明医药股份有限公司 2024-12-31 — — CN disclosed
CN-114746411-B Substituted tricyclic compounds 印度鲁宾有限公司 2024-06-25 — — CN disclosed
EP-4065575-B1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LTD (IN) 2024-01-31 — — EP disclosed
US-20230013778-A1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LIMITED (IN) 2023-01-19 — — US disclosed
EP-4065575-A1 SUBSTITUTED TRICYCLIC COMPOUNDS Lupin Limited (IN) 2022-10-05 — — EP disclosed
CN-114746411-A Substituted tricyclic compounds 印度鲁宾有限公司 2022-07-12 — — CN disclosed
US-20220081427-A1 INHIBITORS OF JUN N-TERMINAL KINASE IMAGO PHARMACEUTICALS, INC. (US) 2022-03-17 — — US disclosed
WO-2021105960-A1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LIMITED (IN) 2021-06-03 — — WO disclosed
EP-2393806-A1 INHIBITORS OF JUN N-TERMINAL KINASE Elan Pharmaceuticals Inc. (US) 2011-12-14 — — EP disclosed
US-20110092495-A1 COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2011-04-21 — — US disclosed
EP-2289890-A1 Compounds for the treatment of multi-drug resistant bacterial infections AstraZeneca AB (SE) 2011-03-02 — — EP disclosed
US-7875715-B2 6-[({1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; antibacteria; methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative staphylococci (MRCNS), penicillin-resistant Streptococcus pneumoniae ASTRAZENECA AB (SE) 2011-01-25 — — US disclosed
US-20100331335-A1 Inhibitors of Jun N-Terminal Kinase ELAN PHARMACETICALS, INC. 2010-12-30 — — US disclosed
WO-2010091310-A1 INHIBITORS OF JUN N-TERMINAL KINASE ELAN PHARMACEUTICALS, INC. (US) 2010-08-12 — — WO disclosed
US-20100152441-A1 COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2010-06-17 — — US disclosed
CN-101243068-A Compounds for the treatment of multi-drug resistant bacterial infections ASTRAZENECA AB (SE) 2008-08-13 — — CN disclosed
EP-1893599-A1 COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS AstraZeneca AB (SE) 2008-03-05 — — EP disclosed
WO-2006134378-A1 COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2006-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230013778-A1 SUBSTITUTED TRICYCLIC COMPOUNDS SOS1, RSU1, KSR1 LMNA 938/4885IDO1 3087/4885MEN1 31/4885
US-20110092495-A1 COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS PIGS, BPGM, IPMK LMNA 2738/4885IDO1 1984/4885MEN1 2771/4885
US-20220081427-A1 INHIBITORS OF JUN N-TERMINAL KINASE CHUK, MAPK6, MAPK3 LMNA 1592/4885IDO1 3528/4885MEN1 4655/4885
US-20100152441-A1 COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS PIGS, BPGM, IPMK LMNA 2738/4885IDO1 1984/4885MEN1 2771/4885
US-12435066-B2 Substituted tricyclic compounds SOS1, RSU1, KSR1 LMNA 938/4885IDO1 3087/4885MEN1 31/4885
US-20100331335-A1 Inhibitors of Jun N-Terminal Kinase CHUK, MAPK6, MAPK3 LMNA 1592/4885IDO1 3528/4885MEN1 4655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.